Opinion|Videos|February 23, 2026
Final Perspectives on APP Contributions to Alzheimer Disease Care
Author(s)Ken Cohen, MD, FACP
Panelists discuss how APPs are essential leaders shaping the future of Alzheimer disease care.
Advertisement
Episodes in this series
Panelists discuss how the Alzheimer care landscape continues to evolve, positioning advanced practice providers (APPs) as central figures in its transformation. Their leadership spans early detection, therapy delivery, and caregiver support.
Panelists discuss how continuous education and collaboration will remain critical as new treatments and technologies emerge. The panel underscores the need for APP empowerment to maintain quality amid rapid scientific change.
Panelists discuss how their collective contributions redefine Alzheimer care as a collaborative, patient-focused endeavor grounded in accessibility, empathy, and innovation.
Advertisement
Related to this article
Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5